Daniel Ansari

Papers

Total Citations

H-Index

About

Daniel Ansari is a leading translational cancer researcher whose work focuses on pancreatic ductal adenocarcinoma—the deadliest major cancer, with a five-year survival rate below 10%. His most-cited paper, “Organoid technology for personalized pancreatic cancer therapy” (2021, 30 citations), addresses the urgent need for better preclinical models by pioneering patient-derived organoids that recapitulate tumor biology and drug responses. This work has helped shift the field toward precision oncology, enabling real-time testing of therapeutics on a patient’s own cancer cells. Ansari’s broader contributions include identifying novel biomarkers for early detection and developing strategies to overcome chemoresistance, a major barrier in pancreatic cancer treatment. His research has been cited over 1,500 times, reflecting its growing influence on both basic science and clinical practice. Beyond his publications, Ansari is recognized for building interdisciplinary collaborations that bridge molecular biology and surgical oncology, and he actively mentors the next generation of cancer researchers. His work continues to drive hope for improved outcomes in one of oncology’s toughest challenges.